The company also amended its credit agreement with its lenders to allow for the acquisition and the use of borrowings under its revolving credit line to fund the acquisition, so long as after such borrowings the balance of the revolving credit line is at or below $400M. In addition, Ryman will receive approximately $11M of existing cash reserves attributable to the assets. (STRS) to acquire Block 21, a mixed-use entertainment, lodging, office, and retail complex located in downtown Austin, Texas, for a total purchase price of $260M, which includes the assumption of approximately $138M of existing mortgage debt. (RHP) announced it reached an agreement with Stratus Properties Inc. We thank the FDA advisory committee for their review and positive recommendation in support of Emergency Use Authorization to help protect this young population."ฤก8:01 EDT Ryman Hospitality to acquire Block 21 from Stratus Properties for $260M - Ryman Hospitality Properties, Inc. In addition, immunizing children will help to get us closer to herd immunity, with the potential to stem the pandemic sooner. cases occur in children 5 to under 12 years of age with a potential risk of complications. "COVID-19 is an ongoing threat for the more than 28 million young children in this age group in the U.S., as they remain at risk for this infection. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. "We appreciated the opportunity to present our clinical data demonstrating the safety and high efficacy of our COVID-19 vaccine in children 5 to under 12 years of age," said Kathrin U. The Data Monitoring Committee for the study has reviewed the data and has not identified any serious safety concerns related to the vaccine. The Phase 2/3 trial showed a favorable safety profile, robust immune responses and a vaccine efficacy rate of 90.7% in participants without prior SARS-CoV-2 infection, measured from 7 days after the second dose. This dose level was carefully selected for use in the trial based on safety, tolerability and immunogenicity data evaluated as part of a dose-ranging study. Participants in this age group received a two-dose regimen of 10-microgram doses administered 21 days apart, one-third of the 30-microgram dose used for people 12 years and older. The committee reviewed the totality of scientific evidence shared by the companies, including results from a Phase 2/3 randomized, controlled trial that included ~4,500 children 5 to less than12 years of age. VRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy. Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee voted 17 to 0, with 1 abstention, to recommend the FDA grant Emergency Use Authorization for the companies' COVID-19 vaccine in children 5 to less than12 years of age. 18:20 EDT Pfizer, BioNTech confirm FDA panel supports EUA for COVID vaccine in children - Pfizer (PFE) and BioNTech (BNTX) announced that the U.S.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |